ProAxsis Limited (www.proaxsis.com) is delighted to announce that it has secured a second licensing agreement with the Queen’s University of Belfast for …
ProAxsis Limited (www.proaxsis.com) is delighted to announce that it has secured a second licensing agreement with the Queen’s University of Belfast for …
ProAxsis will be presenting further data on its ProteaseTag® technology, at the American Thoracic Society Conference, which takes place between May 19th-24th …
Dr David Ribeiro, CEO of ProAxsis, will be attending the Bio-Europe Spring meeting, taking place in Barcelona on March 20th-22nd 2017, and will …
ProAxsis Limited (www.proaxsis.com) is further expanding its ProteaseTag® technology platform, via a project co-funded by the UK’s innovation agency, Innovate UK. ProAxsis …
In a significant new study, a team at the University of Dundee has shown for the first time that sputum neutrophil elastase (NE) activity, …
ProAxsis (www.proaxsis.com) was delighted to observe that measuring active neutrophil elastase (NE) by its ProteaseTag® Active NE Immunoassay was identified as a …
ProAxsis will this week be presenting new data on its ProteaseTag® technology, at the North American Cystic Fibrosis Conference in Orlando, Florida. The …
ProAxsis were this week delighted to host His Royal Highness, the Duke of York, at their new laboratory facilities within the Concourse …
ProAxsis Limited (www.proaxsis.com) is pleased to announce that it has successfully registered a CE Mark for its novel ProteaseTag® Active Neutrophil Elastase …
Dr David Ribeiro, CEO of ProAxsis, will be attending the 16th Biotech in Europe Forum, taking place in Basel on September 27th-28th 2016, …
ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland
tel +44 (0)28 9073 0444
email info@proaxsis.com